

July 27, 2024

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Scrip Code: STAR

The BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Scrip Code: 532531

Dear Sirs,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

Reg: Incorporation of Step-down Wholly Owned Subsidiary in New Zealand

We wish to inform you that Strides Pharma Global Pte. Limited, Singapore, a step-down wholly owned subsidiary of the Company has incorporated a company in New Zealand in the name of "Strides Pharma New Zealand Pty Limited" on July 26, 2024.

Strides New Zealand shall hold market authorizations for the products in New Zealand and shall also undertake trading in pharmaceutical products.

Requisite disclosures in terms of Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 2023 is enclosed as an Annexure.

This is for your kind information and record purpose.

Thanks & Regards, For Strides Pharma Science Limited,

Manjula Ramamurthy Company Secretary ICSI Membership No. A30515

Encl: As above





Disclosure pursuant to Regulation 30 of SEBI Listing Regulation read with SEBI Circular SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023

Incorporation of Step down Wholly owned Subsidiary in New Zealand

#	Details	Information of such event
1.	Name of the target entity, details in brief such as size, turnover, etc.	Strides Pharma New Zealand Pty Limited (Strides New Zealand), Step-down wholly owned subsidiary of the Company, is incorporated as per the laws of New Zealand on July 26, 2024 with company registration number: NZBN: 9429052241956. Strides New Zealand shall hold market authorizations for the products in New Zealand and shall also undertake trading in pharmaceutical products. Strides New Zealand is yet to commence business.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Not applicable as this entity is an new incorporation. Promoters/ promoter group/ group companies are not interested in the transaction.
3.	Industry to which the entity being acquired belongs	Trading/ Marketing of Pharmaceutical products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	Strides Group has a diverse portfolio of products across various therapeutic categories, which are fungible to be commercialized in several regions/ markets. Strides New Zealand was incorporated to leverage the existing product portfolio from US, UK, Australia and other regulated markets to register and sell these products in New Zealand; and to have a local presence to ensure seamless interactions with the Government for participating in local tenders amongst other activities.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not applicable
6.	Indicative time period for completion of the acquisition.	Not applicable



7.	Nature of consideration - whether cash consideration or share swap and details of the same.	Not applicable. The entity is incorporated with a Capital of NZD 15,000.
8.	Cost of acquisition or the price at which the shares are acquired.	
9.	Percentage of shareholding/ control acquired and/ or number of shares acquired.	100% of the Share capital is held by Strides Pharma Global Pte. Limited, Singapore.
10.	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Details as provided above.
